Table 12.
Appropriate indications (median score 7–9)
| Indication | Appropriateness criteria (median score) | |
|---|---|---|
| Detection of CAD: symptomatic—evaluation of chest pain syndrome | ||
| 3 | Intermediate pre-test probability of CAD | A (7) |
| ECG uninterpretable OR unable to exercise | ||
| Detection of CAD: symptomatic—evaluation of intra-cardiac structures | ||
| 5 | Evaluation of suspected coronary anomalies | A (8) |
| Detection of CAD with prior test results—evaluation of chest pain syndrome | ||
| 16 | Uninterpretable or equivocal stress test (exercise, perfusion, or stress echo) | A (8) |
| Risk Assessment with prior test results—asymptomatic | ||
| 20 | Coronary angiography (catheterization or CT) | A (7) |
| Stenosis of unclear significance | ||
| CAD detection in pediatric patients with kawasaki disease—asymptomatic | ||
| 22 | Previous tests (invasive angiography, CMR or CCT) documented coronary aneurysm/stenosis, for follow up | A (7) |
| CAD detection in pediatric patients with kawasaki disease—symptomatic | ||
| 23 | No previous definitive test (invasive angiography, MRCA or CTCA) available | A (7) |
| 24 | Previous tests (angiography, CMR or CCT) documented coronary aneurysm/stenosis, for follow up | A (7) |
| Risk Assessment: preoperative evaluation for cardiac surgery or endovascular intervention—preoperative evaluation | ||
| 28 | Anatomic assessment before percutaneous device closure of ASD or VSD or percutaneous aortic valve replacement | A (7) |
| Structure and function—morphology | ||
| 35 | Assessment of complex congenital heart disease including anomalies of coronary circulation, great vessels, and cardiac chambers and valves | A (8) |
| 36 | Assessment of post-operative congenital heart disease, such as residual pulmonary stenosis, ventricular septal defect and patency check for Blalock-Taussig shunt | A (8) |
| 37 | Evaluation in patients with new onset heart failure to assess etiology | A (8) |
| Structure and function—evaluation of ventricular and valvular function | ||
| 39 | Evaluation of LV function following myocardial infarction OR in heart failure patients | A (9) |
| Patients with technically limited images from echocardiogram | ||
| 38 | Evaluation of LV function following myocardial infarction OR in heart failure patients | A (8) |
| 40 | Quantification of LV function | A(9) |
| Discordant information that is clinically significant from prior tests | ||
| 41 | Evaluation of specific cardiomyopathies (infiltrative [amyloid, sarcoid], HCM, or due to cardiotoxic therapies) | A(9) |
| 42 | Characterization of native and prosthetic cardiac valves | A (7) |
| Patients with technically limited images from echocardiogram or TEE | ||
| 43 | Evaluation for arrhythmogenic right ventricular cardiomyopathy (ARVC) | A (8) |
| Patients presenting with syncope or ventricular arrhythmia | ||
| 44 | Evaluation of myocarditis or myocardial infarction with normal coronary arteries | A(9) |
| Positive cardiac enzymes without obstructive atherosclerosis on angiography | ||
| Structure and function—evaluation of intra- and extra-cardiac structures | ||
| 45 | Evaluation of cardiac mass (suspected tumor or thrombus) | A (9) |
| Patients with technically limited images from echocardiogram or TEE | ||
| 46 | Evaluation of pericardial conditions (pericardial mass, constrictive pericarditis, or complications of cardiac surgery) | A (8) |
| Patients with technically limited images from echocardiogram or TEE | ||
| 47 | Evaluation of pulmonary vein anatomy prior to invasive radiofrequency ablation for atrial fibrillation | A (7) |
| Left atrial and pulmonary venous anatomy including dimensions of veins for mapping purposes | ||
| Structure and function—evaluation of myocardial scar | ||
| 48 | To determine the location and extent of myocardial infarction including ‘no-reflow’ regions | A (9) |
| Post-acute myocardial infarction | ||
| 49 | To detect post PCI myocardial necrosis | A (8) |
| 50 | To determine viability prior to revascularization | A (9) |